Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Anthony Sun Biography and Net Worth

CEO of Zentalis Pharmaceuticals

Dr. Anthony Y. Sun M.D. serves as Independent Director of the Company. He is involved with many private biotechnology companies. Dr. Sun was at Aisling Capital, a private equity firm dedicated to life sciences, from September 2002 until May 2015, during which he held multiple positions most recently as partner. Dr. Sun currently serves on the board of Immusoft Corporation and he previously served on the board of Versartis, Inc. (NASDAQ: VSAR) from January 2013 to October 2018 when it merged with Aravive Biologics, Inc., and on the board of Senex Biotechnology, Inc. Dr. Sun holds a B.S. in Electrical Engineering from Cornell University, an M.D. from Temple University School of Medicine, an M.B.A. from The Wharton School at the University of Pennsylvania, trained in internal medicine at the Hospital of the University of Pennsylvania and was Board Certified in Internal Medicine.

What is Anthony Y. Sun's net worth?: The estimated net worth of Anthony Y. Sun is at least $14.47 million as of April 4th, 2022. Dr. Sun owns 1,175,589 shares of Zentalis Pharmaceuticals stock worth more than $14,471,501 as of April 24th. This net worth estimate does not reflect any other assets that Dr. Sun may own. Learn More about Anthony Y. Sun's net worth.
How do I contact Anthony Y. Sun?: The corporate mailing address for Dr. Sun and other Zentalis Pharmaceuticals executives is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. Zentalis Pharmaceuticals can also be reached via phone at 212-433-3791 and via email at [email protected]. Learn More on Anthony Y. Sun's contact information.
Has Anthony Y. Sun been buying or selling shares of Zentalis Pharmaceuticals?: Anthony Y. Sun has not been actively trading shares of Zentalis Pharmaceuticals during the past quarter. Most recently, Anthony Y. Sun sold 10,471 shares of the business's stock in a transaction on Monday, April 4th. The shares were sold at an average price of $48.50, for a transaction totalling $507,843.50. Following the completion of the sale, the chief executive officer now directly owns 1,175,589 shares of the company's stock, valued at $57,016,066.50. Learn More on Anthony Y. Sun's trading history.
Who are Zentalis Pharmaceuticals' active insiders?: Zentalis Pharmaceuticals' insider roster includes Kimberly Blackwell (Director), Kevin Bunker (COO), Melissa Epperly (CFO), Cam Gallagher (Director), David Johnson (Director), Alexis Pinto (Insider), Anthony Sun (CEO), and Dimitris Voliotis (SVP). Learn More on Zentalis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Zentalis Pharmaceuticals?: In the last twelve months, Zentalis Pharmaceuticals insiders bought shares 3 times. They purchased a total of 4,782,000 shares worth more than $108,081,010.00. In the last twelve months, insiders at the sold shares 7 times. They sold a total of 132,624 shares worth more than $3,613,314.60. The most recent insider tranaction occured on February, 12th when CFO Melissa B Epperly sold 2,573 shares worth more than $29,435.12. Insiders at Zentalis Pharmaceuticals own 6.1% of the company. Learn More about insider trades at Zentalis Pharmaceuticals.
Information on this page was last updated on 2/12/2024.

Anthony Y. Sun Insider Trading History at Zentalis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/4/2022	Sell	10,471	$48.50	$507,843.50	1,175,589
3/1/2022	Sell	10,471	$49.79	$521,351.09
2/14/2022	Sell	4,733	$50.23	$237,738.59
2/1/2022	Sell	10,471	$57.58	$602,920.18
1/3/2022	Sell	10,471	$80.07	$838,412.97
12/1/2021	Sell	10,471	$77.98	$816,528.58
11/1/2021	Sell	10,471	$81.44	$852,758.24
10/4/2021	Sell	26,799	$66.33	$1,777,577.67
9/1/2021	Sell	26,794	$67.50	$1,808,595.00
8/2/2021	Sell	19,015	$51.03	$970,335.45
7/6/2021	Sell	25,045	$46.90	$1,174,610.50
7/1/2021	Sell	26,794	$51.21	$1,372,120.74
6/1/2021	Sell	26,794	$54.03	$1,447,679.82	1,423,491
5/3/2021	Sell	26,794	$59.32	$1,589,420.08	1,474,161
4/5/2021	Sell	64,562	$43.43	$2,803,927.66	1,743,479
1/4/2021	Sell	26,794	$52.06	$1,394,895.64	1,804,005
12/7/2020	Sell	35,606	$53.52	$1,905,633.12	2,074,567
12/4/2020	Sell	39,769	$50.98	$2,027,423.62	2,074,567
12/2/2020	Sell	26,794	$51.40	$1,377,211.60	2,116,363
11/23/2020	Sell	15,408	$46.53	$716,934.24	2,146,568
4/7/2020	Buy	888	$18.00	$15,984.00	2,146,568

Anthony Y. Sun Buying and Selling Activity at Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Company Overview

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Today's Range

Now: $12.31

$12.20

$12.59

50 Day Range

MA: $14.16

$11.95

$16.13

2 Week Range

Now: $12.31

$9.56

$31.46

Volume

107,553 shs

Average Volume

787,767 shs

Market Capitalization

$873.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad